TB vaccine: latest news

TB vaccine in your own words

TB vaccine news from aidsmap

  • TB vaccine halves risk of disease in people with latent TB

    A vaccine against tuberculosis (TB) reduced the risk of developing active TB in HIV-negative people with latent TB infection by 54% in a large phase 2b study published last month in The New England Journal of Medicine. TB is ...

    10 October 2018 | Keith Alcorn
  • Researchers see further positive results with herpes virus-based vaccines in monkeys

    One of the biggest news stories at the AIDS Vaccine 2013 conference was the groundbreaking experiment in which half of a group of monkeys given a candidate monkey-HIV vaccine appeared to lose all trace of viral infection. This vaccine ...

    09 October 2013 | Gus Cairns
  • Results of TB vaccine trial give cause for optimism, say researchers

    Results of a trial have been praised for “providing hard evidence about protection against tuberculosis in human beings”. The MVA85A vaccine did not confer any additional protection against tuberculosis (TB) or infection with Mycobacterium tuberculosis to infants who had ...

    04 February 2013 | Michael Carter
  • BCG vaccination causes immune activation of CD4 T-cells in infants

    BCG vaccination, routinely given at birth to protect from tuberculosis (TB), causes an immune-activation of CD4 T cells, the HIV target cells, according to a South African study presented at the Nineteenth International AIDS Conference in Washington DC. This immune ...

    31 July 2012 | Lesley Odendal
  • Therapeutic TB vaccine could reduce latent TB treatment to one month

    A vaccine, designed to be used alongside isoniazid preventive therapy to shorten the course of drug treatment in people with latent TB, will shortly undergo trials in South Africa, manufacturer Archivel Farma announced this week. Latent infection ...

    06 May 2010 | Keith Alcorn
  • Trial of TB vaccine candidate begins in people with HIV

    Crucell and the Aeras Global TB Vaccine Foundation today announced the start of a Phase II clinical trial of the jointly developed tuberculosis (TB) vaccine candidate AERAS-402/Crucell Ad35 in HIV infected adults. The Phase II study is ...

    14 April 2010 | Press Release
More news

TB vaccine news selected from other sources

  • GSK candidate vaccine helps prevent active pulmonary tuberculosis in HIV negative adults in phase II study

    Today, GSK and Aeras reported that GSK’s M72/AS01E[1] candidate vaccine significantly reduced the incidence of pulmonary tuberculosis disease in HIV-negative adults with latent tuberculosis infection[2] in an ongoing phase IIb clinical trial testing. These primary results published in the New England Journal of Medicine after two years of trial demonstrate an overall vaccine efficacy of 54%, with varied response rates observed in different demographic sub-groups.

    26 September 2018 | Aeras
  • TB vaccine trial results offer potential for BCG Revaccination, hope for subunit vaccines

    Aeras, a nonprofit organization dedicated to developing vaccines against tuberculosis (TB), today announced results from an innovative clinical trial that provides encouraging new evidence that TB vaccines could prevent sustained infections in high-risk adolescents. In a prevention-of-infection Phase 2 trial conducted in South Africa, revaccination with the Bacille Calmette-Guerin (BCG) vaccine significantly reduced sustained TB infections in adolescents. An experimental vaccine candidate, H4:IC31, also reduced sustained infections, although not at statistically significant levels.

    19 February 2018 | Eurekalert Medicine & Health
  • The 2017 Pipeline Report

    Treatment Action Group (TAG) announces the launch of its annual research and development landscape analysis: The Pipeline Report: Drugs, Diagnostics, Vaccines, Preventive Technologies, Research Toward a Cure, and Immune-Based and Gene Therapies in Development.

    19 July 2017 | Treatment Action Group
  • Quest for tuberculosis vaccine begins as scientists aim to beat disease by 2035

    In South Africa and beyond, thousands of TB cases emerge each year despite the BCG vaccine. An ambitious plan seeks to end what has become a global epidemic.

    12 January 2016 | The Guardian
  • First results of tuberculosis vaccine candidate MTBVAC very promising

    A phase I safety study of TB vaccine candidate MTBVAC, the first live-attenuated Mycobacterium  tuberculosis-based vaccine to enter clinical trials, shows very good results in the first intermediate analysis.

    18 November 2013 | TuBerculosis Vaccine Initiative
  • TB vaccine business case: lifesaving TB vaccines feasible

    The global tuberculosis (TB) epidemic annually causes 1.4 million deaths and is estimated to cost the global economy €290 billion per year. Vaccines that could prevent people from acquiring, developing and transmitting disease would be the single most effective tool in mitigating this epidemic. Making new TB vaccines available to the world over the next 10-15 years is estimated to cost approximately €600 million, utilizing a highly efficient portfolio approach and adequate funding.

    12 June 2013 | Tuberculosis Vaccine Initiative
  • Global scientific experts convene in Cape Town to report on progress toward tuberculosis vaccines

    At a time of growing global concern about the rising level of drug-resistant strains of tuberculosis in South Africa and worldwide, the world's top TB vaccine experts are meeting this week, the first time this scientific forum has been held in Africa, where they will present new research aimed at advancing development of vaccines against the deadly airborne disease.

    25 March 2013 | Eurekalert Inf Dis
  • Injection-free vaccination technique could address global vaccine challenge for diseases such as HIV and malaria

    Scientists at King’s College London have demonstrated the ability to deliver a dried live vaccine to the skin without a traditional needle, and shown for the first time that this technique is powerful enough to enable specialised immune cells in the skin to kick-start the immunising properties of the vaccine.

    11 February 2013 | Kings College London press release
  • Data from Historic Phase IIb Clinical Trial for Tuberculosis Vaccine Candidate MVA85A Published in The Lancet

    Vaccine candidate did not provide statistically-significant protection in preventing TB disease in infants previously vaccinated with BCG.

    04 February 2013 | Aeras
  • TB Vaccine Safe but Does Not Confer Protection, Calls for Redoubling Efforts on Global TB Vaccine Portfolio

    The clinical trial of the TB vaccine candidate MVA85A was a Phase IIb safety and efficacy trial in 2,797 infants living in the Western Cape province of South Africa. The candidate was safe and well tolerated in the population tested.

    04 February 2013 | Aeras
More news

Our information levels explained

  • Short and simple introductions to key HIV topics, sometimes illustrated with pictures.
  • Expands on the previous level, but also written in easy-to-understand plain language.
  • More detailed information, likely to include medical and scientific language.
  • Detailed, comprehensive information, using medical and specialised language.
Community Consensus Statement on Access to HIV Treatment and its Use for Prevention

Together, we can make it happen

We can end HIV soon if people have equal access to HIV drugs as treatment and as PrEP, and have free choice over whether to take them.

Launched today, the Community Consensus Statement is a basic set of principles aimed at making sure that happens.

The Community Consensus Statement is a joint initiative of AVAC, EATG, MSMGF, GNP+, HIV i-Base, the International HIV/AIDS Alliance, ITPC and NAM/aidsmap
close

This content was checked for accuracy at the time it was written. It may have been superseded by more recent developments. NAM recommends checking whether this is the most current information when making decisions that may affect your health.

NAM’s information is intended to support, rather than replace, consultation with a healthcare professional. Talk to your doctor or another member of your healthcare team for advice tailored to your situation.